Brief: Coeptis Therapeutics Completes Exclusive License For Immuno-Oncology Platform From Deverra Therapeutics
17/08/2023 12:36
Aug 17 (Reuters) - Coeptis Therapeutics Holdings Inc
COEP.O :
* COEPTIS THERAPEUTICS COMPLETES EXCLUSIVE LICENSE FOR
ALLOGENEIC
IMMUNO-ONCOLOGY PLATFORM AND CLINICAL STAGE ASSETS FROM DEVERRA
THERAPEUTICS
* COEPTIS THERAPEUTICS - UNDER DEAL, CO PAID TO DEVERRA
ABOUT
$570,000 IN CASH AND ISSUED TO DEVERRA 4,000,000 SHARES OF
COEPTIS' COMMON STOCK
Source text for Eikon: ID:nPn7L0MFqa
Further company coverage: COEP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Z Squared (Delaware)
See all newsBrief: Z Squared Inc. Signs Definitive Agreement To Acquire 100% Of Paradox Data And Its Union County Campus
Brief: Z Squared, Inc. To Acquire Majority Interest In Paradox Data And Its Union County Campus, A Next-Generation Data Center Development Targeting Up To 150 MW Of Firm Power
Brief: Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement To Support Ai Infrastructure Buildout
Brief: Z Squared Appoints Jon Najarian, Pete Najarian, Marc Lopresti And Jay Zapata To Newly Formed Advisory Board
Brief: Z Squared Announces Executive Leadership Appointments To Advance Ai Infrastructure Strategy